论文部分内容阅读
目的 评价多索茶碱联合头孢他啶治疗老年慢性肺气肿的临床效果。方法 将2015年3月至2018年1月我院收治的80例老年肺气肿患者作为研究对象，遵循数字表随机原则分两组，即对照组40例给予多索茶碱注射液治疗，分析组40例则于对照组的基础上联合头孢他啶治疗，比较两组患者临床疗效、肺功能改善效果及健康状况。结果 ①分析组治疗总有效率为87.50%（35/40）明显高于对照组67.50%（27/40），两组患者基线资料差异具有统计学意义（P＜0.05）。②两组患者治疗前一秒用力呼气容积占预计值百分比（FEV1%）“,”Objective To evaluate the clinical effect of doxophylline combined with ceftazidine in the treatment of chronic emphysema in the elderly. Methods From March 2015 to January 2018， our hospital 80 cases of senile emphysema patients as the research object， follow the principle of digital meter randomly divided into two groups， namely the control group of 40 cases of doxofylline injection was given analysis group， the 40 cases in the analysis group were treated with ceftazidime on the basis of the control group， compared two groups of patients\' clinical curative effect， improve lung function and health ef fect. Results (1)The total effective rate in the analysis group was 87.50% (35/40)， which was significantly higher than 67.50% (27/40) in the control group. The difference in baseline data between the two groups was statistically significant (P ＜0.05). (2)The percentage of forced expiratory volume (FEV1%)， maximum expiratory interruption flow (MMEF)， and maximum expiratory air velocity (PEF) in the two groups before treatment was not significantly different (P ＞0.05). After treatment， the improvement effect in the analysis group was significantly better than that in the control group， and the difference was statistically significant (P ＜0.05). (3)There was no statistically significant difference in SF-36 score between the two groups before treatment (P ＞0.05). After treatment， the score of the analysis group was significantly higher than that of the control group， and the difference was statistically significant (P ＜0.05). Comparison of adverse reactions between the two groups， P ＞0.05. Conclusion In the treatment of elderly patients with chronic emphysema， there is still a lot of room for progress in conventional doxofylline treatment. The combination of doxofylline and ceftazidime can achieve ideal curative effect and can effectively improve the pulmonary function and quality of life of patients. It is worthy of clinical application.